million
infect
due
ar
pathogen
attribut
death
year
ar
still
real
problem
unit
state
given
sicker
patient
tend
acquir
resist
varieti
pathogen
also
suffer
wors
consequ
result
inadequ
empir
target
therapi
critic
ill
patient
repres
larg
proport
burden
particularli
worst
hit
follow
five
resist
pathogen
type
consid
pose
urgent
threat
carbapenemresist
acinetobact
carbapenemresist
enterobacteriacea
cre
candida
auri
drugresist
neisseria
gonorrhoea
drugresist
clostridioid
difficil
latter
consequ
resist
pathogen
antibiot
therapi
present
nearli
extendedspectrum
esbl
enterobacteriacea
infect
occur
among
hospit
patient
unit
state
repres
alarm
increas
last
half
decad
particularli
sober
given
late
less
gramneg
pathogen
report
resist
thirdgener
cephalosporin
unit
state
clonal
spread
led
global
dissemin
esbl
among
enterobacteriacea
predominantli
outcom
notori
success
longterm
polyamor
relationship
among
effici
carrier
plasmid
virul
strain
escherichia
coli
resili
resist
gene
today
human
gut
anim
environment
reservoir
esbl
surpris
larg
proport
enterobacteriacea
esbl
infect
report
cdc
origin
commun
recent
random
clinic
trial
demonstr
lack
noninferior
piperacillintazobactam
meropenem
esbl
e
coli
klebsiella
pneumonia
bacteremia
like
potenti
carbapenem
use
uncommon
infect
turn
may
drive
carbapenem
resist
rate
futur
furthermor
fear
cover
esblproduc
pathogen
patient
present
sepsi
like
drive
empir
carbapenem
therapi
especi
among
esblspecif
risk
factor
howev
recent
studi
demonstr
preval
esbl
enterobacteriacea
patient
cultureposit
sepsi
us
hospit
still
fact
less
may
mitig
fear
extent
furthermor
plasmid
carri
esbl
gene
often
carri
clinic
import
resist
gene
well
encod
carbapenemas
product
may
result
gramneg
pathogen
display
difficulttotreat
resist
dtr
resist
highefficaci
lowtox
antibiot
pose
manag
dilemma
provid
shown
portend
wors
prognosi
multipl
us
intern
studi
virtu
seriou
ill
caus
groupa
streptococci
ga
bloodstream
infect
streptococc
toxic
shock
syndrom
necrot
softtissu
infect
critic
care
provid
particular
tend
encount
pathogen
frequent
rate
clindamycin
resist
ga
increas
rather
drastic
year
suggest
one
everi
five
ga
pathogen
encount
current
practic
like
clindamycin
resist
base
infecti
diseas
societi
america
surgic
infect
societi
guidelin
recommend
standard
practic
use
clindamycin
adjunct
antitoxin
properti
seriou
invas
groupa
streptococc
infect
necrot
fasciiti
toxic
shock
syndrom
although
evid
anim
studi
suggest
clindamycin
antitoxin
activ
may
preserv
even
clindamycinresist
ga
definit
demonstr
human
given
high
casefat
rate
seriou
invas
ga
infect
unclear
benefit
adjunct
therapi
iv
immunoglobulin
absenc
clindamycin
ongo
loss
clindamycin
activ
ga
nation
alarmingli
high
rate
clindamycin
resist
elsewher
repres
sober
consequ
ar
crisi
critic
care
provid
may
continu
experi
worldwid
although
candid
ga
vaccin
evalu
long
way
vaccin
implement
everyday
practic
invas
diseas
due
streptococci
uncommon
may
clinic
indistinguish
ga
present
tradit
thought
pathogen
impact
predominantli
pregnant
patient
neonat
group
b
streptococc
gb
infect
increasingli
recogn
import
pathogen
caus
invas
diseas
adult
especi
chronic
condit
diabet
obes
importantli
accord
ar
threat
report
around
gb
remain
resist
clindamycin
nearli
one
two
chanc
clindamycin
may
inact
pathogen
gb
clinic
effect
adjunct
pathogen
vivo
remain
unclear
clinic
import
streptococci
group
c
group
g
also
notori
caus
invas
diseas
includ
report
drugresist
candida
speci
gener
nonalbican
varieti
respons
candida
bloodstream
infect
unit
state
encount
manag
critic
care
provid
although
cdc
report
reassur
declin
overal
drugresist
candida
isol
also
alert
us
case
year
highli
resist
fungu
c
auri
report
although
first
isol
ear
woman
japan
pathogen
first
report
occur
unit
state
howev
compar
cdc
report
incid
tripl
alarm
rate
growth
incid
potenti
display
resist
routin
use
antifung
agent
unaccept
high
associ
mortal
rate
earn
c
auri
urgent
threat
statu
case
cluster
new
york
new
jersey
illinoi
sever
state
report
least
one
case
critic
care
provid
must
keep
close
eye
deadli
pathogen
result
outbreak
unmanag
spread
even
warrant
icu
shut
critic
care
provid
often
privi
outcom
patient
transfer
icu
howev
highli
motiv
respons
outcom
data
avail
one
stress
enough
import
demonstr
critic
care
provid
effort
prevent
infect
go
thankless
fact
work
certainli
bolster
ongo
complianc
effort
highli
resist
gramneg
taxa
gener
affect
debilit
patient
display
high
propens
caus
icu
outbreak
critic
ill
death
declin
even
stabil
incid
certainli
good
news
antibiot
armamentarium
carbapenemresist
acinetobact
baumannii
remain
limit
even
though
colistin
often
activ
pathogen
gener
backbon
treatment
regimen
associ
heteroresist
suboptim
efficaci
high
toxic
make
colistin
less
ideal
option
combin
colistin
agent
carbapenem
rifampin
shown
offer
signific
increment
benefit
thu
far
howev
light
scarc
option
combin
regimen
must
continu
explor
although
often
activ
carbapenemresist
baumannii
tigecyclin
also
suboptim
primarili
due
low
blood
level
toxic
concern
suggest
excess
associ
mortal
sulbactam
effect
remain
activ
small
minor
carbapenemresist
isol
sever
gramneg
antibiot
approv
last
half
decad
cefiderocol
drug
demonstr
vitro
activ
sizabl
proport
carbapenemresist
baumannii
isol
although
recent
approv
complic
urinari
tract
infect
uti
due
gramneg
pathogen
lack
routin
treatment
option
warn
label
higher
allcaus
mortal
patient
carbapenemresist
gramneg
infect
place
paus
candidaci
much
anticip
goto
drug
carbapenemresist
baumannii
complex
infect
critic
ill
patient
favor
evid
becom
avail
therapi
bacteriophag
monoclon
antibodi
promis
evid
still
evolv
reason
safe
say
carbapenemresist
baumannii
complex
infect
remain
critic
care
provid
worst
nightmar
multidrug
resist
p
aeruginosa
usual
consequ
sever
potenti
intrins
adapt
resist
mechan
play
although
suggest
resist
may
diminish
virul
potenti
univers
true
virul
epidem
highrisk
clone
multidrug
resist
mdr
extensivelydrug
resist
xdr
univers
true
virul
epidem
highrisk
clone
mdrxdr
p
aeruginosa
caus
number
outbreak
worldwid
therapeut
standpoint
pictur
less
grim
carbapenemresist
p
aeruginosa
vast
major
fact
dtr
compar
carbapenemresist
baumannii
ceftolozanetazobactam
ceftazidimeavibactam
food
drug
administr
approv
complic
uti
intraabdomin
infect
hospitalventilatoracquir
pneumonia
display
vitro
activ
mani
isol
mdr
carbapenemresist
p
aeruginosa
demonstr
moder
treatment
success
observ
studi
despit
lack
dedic
trial
patient
mdr
p
aeruginosa
pool
clinic
trial
data
ceftazidimeavibactam
trial
suggest
compar
efficaci
carbapenem
activ
like
see
newer
agent
use
often
mdrxdr
p
aeruginosa
lieu
older
toxic
altern
colistin
tigecyclin
last
decad
cre
becom
global
menac
carbapenem
resist
enterobacteriacea
predominantli
confer
varieti
trait
eg
k
pneumonia
carbapenemas
new
delhi
nmd
oxacillinasetyp
verona
integronco
imipenemas
lead
carbapenemas
product
access
toxic
lessefficaci
antibiot
avail
cre
howev
thank
collect
effort
govern
legisl
profession
societi
industri
feder
intern
agenc
lesser
toxic
antibiot
recent
approv
becom
avail
use
includ
ceftazidimeavibactam
meropenemvaborbactam
eravacyclin
cefiderocol
demonstr
vitro
activ
number
cre
new
antibiot
ceftazidimeavibactam
activ
cre
use
difficulttotreat
infect
base
safeti
efficaci
gramneg
pathogen
trial
led
approv
observ
studi
patient
specif
cre
infect
demonstr
superior
effect
colistin
yet
colistin
found
use
often
ceftazidimeavibactam
throughout
first
year
follow
approv
ceftazidimeavibactam
like
reflect
combin
provid
reluct
due
unclear
efficaci
sicker
septic
patient
lack
treatment
experi
awar
inhous
vitro
test
infrastructur
well
higher
cost
furthermor
differ
cre
may
display
vari
suscept
new
agent
depend
speci
trait
result
resist
carbapenem
instanc
treatment
produc
eg
pathogen
display
often
still
necessit
relianc
older
agent
colistin
combin
old
new
agent
exampl
aztreonam
ceftazidimeavibactam
avibactam
compon
detail
review
therapeut
option
cre
beyond
scope
foreword
found
elsewher
declin
incid
infect
due
highli
resist
gramneg
pathogen
certainli
good
news
although
still
prematur
make
causal
infer
observ
decreas
specif
pathogen
host
behavior
societ
factor
observ
speak
success
current
implement
batteri
infect
control
prevent
strategi
strongli
suggest
keep
effort
apart
univers
precaut
specif
intervent
increas
use
screen
rectal
swab
activ
screen
use
molecular
test
cohort
patient
base
detect
highli
transmiss
carbapenemas
gene
continu
contact
precaut
end
hospit
subsequ
stay
may
help
howev
implement
intervent
conting
resourc
personnel
infrastructur
vari
nation
impact
intervent
difficult
evalu
larg
scale
well
recogn
previou
studi
rate
methicillinresist
aureu
mrsa
among
hospit
patient
declin
last
decad
unit
state
remark
decreas
mrsa
infect
veteran
health
administr
hospit
attribut
cdc
recommend
screen
track
contact
isol
hand
wash
heighten
employe
respons
prevent
mrsa
infect
per
ar
threat
report
hospitalonset
mrsa
infect
decreas
nearli
fifth
unit
state
although
hospitalonset
mrsa
bloodstream
infect
decreas
interestingli
signific
decreas
observ
recent
portion
period
ie
prevent
effort
maxim
satur
begin
slack
effort
regardless
infect
mrsa
still
remain
major
problem
one
common
ar
pathogen
encount
us
hospit
communityonset
mrsa
bloodstream
infect
decreas
less
vigor
per
year
persist
commun
tie
opioid
crisi
associ
inject
drug
use
infect
due
vancomycinresist
enterococcu
vre
gener
occur
patient
longterm
care
facil
well
critic
ill
immun
compromis
patient
transplant
recipi
vre
rate
display
reassur
declin
although
still
rel
rare
remain
concern
ongo
emerg
treatmentlimit
varieti
vre
also
display
resist
linezolid
andor
nonsuscept
daptomycin
two
agent
current
repres
antibiot
bedrock
manag
vre
infect
although
directli
consequ
resist
pathogen
c
difficil
like
ar
close
tie
indiscrimin
use
antibiot
ar
report
us
rate
c
diseas
decreas
least
part
decreas
attribut
decreas
use
fluoroquinolon
antibiot
associ
strain
c
difficil
notori
caus
sever
diseas
unfortun
c
difficil
remain
rel
common
occurr
icu
unit
state
today
especi
true
among
greater
healthcar
contact
longterm
care
resid
older
recent
hospit
patient
associ
high
burden
morbid
mortal
henc
effort
prevent
c
diseas
includ
antibiot
stewardship
contact
isol
facil
clean
hand
wash
well
prompt
detect
treatment
must
emphas
among
healthcar
provid
reassur
number
report
death
attribut
ar
decreas
around
methodolog
appli
estim
arattribut
death
cdc
ar
report
set
way
decreas
death
direct
reflect
decreas
infect
incid
decreas
incid
infect
due
mani
highmort
risk
pathogen
describ
translat
live
save
conclus
ar
threat
report
provid
us
data
healthcar
commun
proud
certainli
pretext
complac
effort
necessari
need
hour
practic
guidelin
manag
ar
pathogen
includ
guidanc
empir
use
newli
approv
agent
ar
strongli
suspect
present
urgent
need
frontlin
provid
seat
tabl
antibiot
polici
advocaci
field
like
benefit
physician
investig
dualli
train
infecti
diseas
critic
care
medicin
pathway
curricula
traine
better
delin
need
enhanc
evid
base
overlap
ar
sepsi
need
better
guidanc
best
use
interpret
rapid
diagnost
along
wider
implement
support
outcomebas
assess
util
way
highstak
treatment
decis
frontlin
base
truth
rather
fear
empiric
field
ar
complex
time
overwhelm
yet
everi
critic
care
provid
must
continu
play
part
familiar
evolv
nomenclatur
pathogen
resist
emerg
trend
key
genotyp
resist
trait
import
therapeut
implic
patient
sincer
hope
recognit
exist
concentr
sphere
ar
among
frontlin
provid
offer
constant
remind
direct
action
bedsid
fact
silo
taken
togeth
farreach
implic
popul
thank
ms
kelli
byrn
assist
prepar
figur
